Highly multiplexed live-cell gpcr arrays for drug discovery in glioma

This Project Grant from the National Institutes of Health's National Cancer Institute totaling $668,151 will support the development of highly multiplexed live-cell G protein-coupled receptor (GPCR) arrays for glioma drug discovery. Spectragenetics, Inc. will deploy an automated multiplexed live-cell assay to detect and quantify agonist and inverse-agonist activities against 55 GPCRs known to be upregulated or downregulated in human gliomas. The assay will be used to screen 48 established glioblastoma cell lines from the Human Glioblastoma Cell Culture Resource for secretions affecting any of the 55 receptors. This work under the Cancer Treatment Research program (CFDA 93.395) aims to identify new leads towards anti-tumor therapeutics and provide a platform for detecting such leads in tumor tissue and chemical or biologic libraries.

Abstract

We will deploy an automated multiplexed live-cell assay to detect and quantify agonist and inverse-agonist activities against 55 gpcrs known to be upregulated or downregulated in human gliomas. The assay will be used to look for the secretion of effectors for any of the 55 receptors by 48 established glioma cell lines of the human glioblastoma cell culture resource. This endeavor may yield new leads towards the development of anti-tumor therapeutics, and will provide a platform for detecting such leads in resected tumor tissue and in chemical or biologic libraries in future experiments.